细胞靶向肽在多肽偶联药物中的研究进展  

Research Progress of Cell-Targeting Peptides in PDC

作　　者：任文杰 周昊 刘梦瑶 李帅 史潇瑀 刘文涛 REN Wen-jie;ZHOU Hao;LIU Meng-yao;LI Shuai;SHI Xiao-yu;LIU Wen-tao(Shandong Academy of Pharmaceutical Science,Key Laboratory for Biopharmaceuticals Research of Shandong Province,Jinan 250101,China)

机构地区：[1]山东省药学科学院山东省生物药物重点实验室,山东济南250101

出　　处：《精细化工中间体》2023年第2期1-7,39,共8页Fine Chemical Intermediates

摘　　要：靶向治疗利于提高治疗效率,减少不良反应,克服耐药性,特别在癌症治疗领域被广泛运用。多肽偶联药物(PDC)由归巢肽、连接臂和具有药理作用的有效载荷构成。其中归巢肽包括细胞穿透肽(CPP)及细胞靶向肽(CTP),在整个分子中作用重要,决定了分子穿透生物膜并靶向特定靶标的能力。介绍了PDC中CTP的种类、递送药物的应用等,为CTP及其用于新型PDC研发提供指导,推进新型PDC的研发进程。Targeted therapy can improve treatment efficiency,reduce adverse reactions and overcome drug resistance,especially in the field of cancer treatment.Peptide-drug conjugate(PDC)is composed of homing peptide,linker and payload with pharmacological effects.The homing peptide includes cell penetrating peptide(CPP)and cell targeting peptide(CTP).Peptide moieties play a crucial role in the whole molecule,and they determine the ability of the molecule to penetrate the biofilm and target specific targets.The types of CTP in PDC and its application in drug delivery are introduced.It is expected to increase researchers′understanding of CTP and PDC and promote the research and development process of new PDC.

关 键 词：多肽偶联药物 细胞靶向肽 RGD肽 NGR肽 促黄体激素释放激素 Lyp-1 

分 类 号：R979.1[医药卫生—药品]